(Q44667656)

reason for preferred rank

5 December 2017

title

Treatment of the acquired immune deficiency syndrome—related Kaposi's sarcoma with bleomycin as a single agent (English)

1 reference

10.1002/1097-0142(19901101)66:9<1869::AID-CNCR2820660903>3.0.CO;2-S

https://api.crossref.org/works/10.1002/1097-0142(19901101)66:9%3C1869::AID-CNCR2820660903%3E3.0.CO;2-S

2 November 2022

Treatment of the acquired immune deficiency syndrome-related Kaposi's sarcoma with bleomycin as a single agent (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1699652

2 November 2022

1 reference

1 reference

10.1002/1097-0142(19901101)66:9<1869::AID-CNCR2820660903>3.0.CO;2-S

https://api.crossref.org/works/10.1002/1097-0142(19901101)66:9%3C1869::AID-CNCR2820660903%3E3.0.CO;2-S

2 November 2022

3

Katlama C

1 reference

5 December 2017

K. Lassoued

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1699652

2 November 2022

J. P. Clauvel

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1699652

2 November 2022

M. Janier

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1699652

2 November 2022

C. Picard

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1699652

2 November 2022

S. Matheron

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1699652

2 November 2022

language of work or name

English

0 references

publication date

1 November 1990

1 reference

full work available at URL

5 December 2017

number of pages

4

1 reference

based on heuristic

inferred from page(s)

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2F1097-0142(19901101)66:9%3C1869::AID-CNCR2820660903%3E3.0.CO;2-S

1 reference

10.1002/1097-0142(19901101)66:9<1869::AID-CNCR2820660903>3.0.CO;2-S

https://api.crossref.org/works/10.1002/1097-0142(19901101)66:9%3C1869::AID-CNCR2820660903%3E3.0.CO;2-S

https://onlinelibrary.wiley.com/doi/full/10.1002/1097-0142(19901101)66:9%3C1869::AID-CNCR2820660903%3E3.0.CO;2-S

2 November 2022

1 reference

10.1002/1097-0142(19901101)66:9<1869::AID-CNCR2820660903>3.0.CO;2-S

https://api.crossref.org/works/10.1002/1097-0142(19901101)66:9%3C1869::AID-CNCR2820660903%3E3.0.CO;2-S

2 November 2022

1 reference

5 December 2017

volume

66

1 reference

5 December 2017

issue

9

1 reference

5 December 2017

page(s)

1869-1872

1 reference

Acquired Immunodeficiency Syndrome: Epidemiologic, Clinical, Immunologic, and Therapeutic Considerations

5 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2819901101%2966%3A9%3C1869%3A%3AAID-CNCR2820660903%3E3.0.CO%3B2-S

Vinblastine therapy for Kaposi's sarcoma in the acquired immunodeficiency syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2819901101%2966%3A9%3C1869%3A%3AAID-CNCR2820660903%3E3.0.CO%3B2-S

Combined zidovudine and interferon-alpha therapy in patients with Kaposi sarcoma and the acquired immunodeficiency syndrome (AIDS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2819901101%2966%3A9%3C1869%3A%3AAID-CNCR2820660903%3E3.0.CO%3B2-S

Zidovudine in patients with human immunodeficiency virus (HIV) infection and Kaposi sarcoma. A phase II randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2819901101%2966%3A9%3C1869%3A%3AAID-CNCR2820660903%3E3.0.CO%3B2-S

Combination chemotherapy of disseminated Kaposi's sarcoma in patients with the acquired immune deficiency syndrome

21 January 2018

5

1 reference

10.1002/1097-0142(19901101)66:9<1869::AID-CNCR2820660903>3.0.CO;2-S

https://api.crossref.org/works/10.1002/1097-0142(19901101)66:9%3C1869::AID-CNCR2820660903%3E3.0.CO;2-S

Chemotherapy in advanced Kaposi's sarcoma. Implications for current cases in homosexual men.

2 November 2022

6

1 reference

10.1002/1097-0142(19901101)66:9<1869::AID-CNCR2820660903>3.0.CO;2-S

https://api.crossref.org/works/10.1002/1097-0142(19901101)66:9%3C1869::AID-CNCR2820660903%3E3.0.CO;2-S

Vincristine and Kaposi's sarcoma in the acquired immunodeficiency syndrome

2 November 2022

7

1 reference

10.1002/1097-0142(19901101)66:9<1869::AID-CNCR2820660903>3.0.CO;2-S

https://api.crossref.org/works/10.1002/1097-0142(19901101)66:9%3C1869::AID-CNCR2820660903%3E3.0.CO;2-S

Treatment of epidemic Kaposi's sarcoma with etoposide or a combination of doxorubicin, bleomycin, and vinblastine.

2 November 2022

10

1 reference

10.1002/1097-0142(19901101)66:9<1869::AID-CNCR2820660903>3.0.CO;2-S

https://api.crossref.org/works/10.1002/1097-0142(19901101)66:9%3C1869::AID-CNCR2820660903%3E3.0.CO;2-S

Kaposi's sarcoma in AIDS patients: long-term treatment with recombinant interferon alpha-2a and chemotherapy

2 November 2022

12

1 reference

10.1002/1097-0142(19901101)66:9<1869::AID-CNCR2820660903>3.0.CO;2-S

https://api.crossref.org/works/10.1002/1097-0142(19901101)66:9%3C1869::AID-CNCR2820660903%3E3.0.CO;2-S

Kaposi sarcoma and alpha-interferon therapy

2 November 2022

13

1 reference

10.1002/1097-0142(19901101)66:9<1869::AID-CNCR2820660903>3.0.CO;2-S

https://api.crossref.org/works/10.1002/1097-0142(19901101)66:9%3C1869::AID-CNCR2820660903%3E3.0.CO;2-S

Kaposi's sarcoma and the acquired immune deficiency syndrome. Treatment with recombinant interferon alpha and analysis of prognostic factors

2 November 2022

14

1 reference

10.1002/1097-0142(19901101)66:9<1869::AID-CNCR2820660903>3.0.CO;2-S

https://api.crossref.org/works/10.1002/1097-0142(19901101)66:9%3C1869::AID-CNCR2820660903%3E3.0.CO;2-S

Cytotoxic Drugs and the Granulopoietic System

2 November 2022

15

1 reference

10.1002/1097-0142(19901101)66:9<1869::AID-CNCR2820660903>3.0.CO;2-S

https://api.crossref.org/works/10.1002/1097-0142(19901101)66:9%3C1869::AID-CNCR2820660903%3E3.0.CO;2-S

Clinical and virological effects of high-dose recombinant interferon-alpha in disseminated AIDS-related Kaposi's sarcoma

2 November 2022

18

1 reference

10.1002/1097-0142(19901101)66:9<1869::AID-CNCR2820660903>3.0.CO;2-S

https://api.crossref.org/works/10.1002/1097-0142(19901101)66:9%3C1869::AID-CNCR2820660903%3E3.0.CO;2-S

Cancer chemotherapy reports

2 November 2022

24

57

325

Vogel

1973

1 reference

10.1002/1097-0142(19901101)66:9<1869::AID-CNCR2820660903>3.0.CO;2-S

https://api.crossref.org/works/10.1002/1097-0142(19901101)66:9%3C1869::AID-CNCR2820660903%3E3.0.CO;2-S

2 November 2022

Cancer Treatment Reports

25

62

2011

Sikic

1978

1 reference

10.1002/1097-0142(19901101)66:9<1869::AID-CNCR2820660903>3.0.CO;2-S

https://api.crossref.org/works/10.1002/1097-0142(19901101)66:9%3C1869::AID-CNCR2820660903%3E3.0.CO;2-S

2 November 2022

Cancer Treatment Reports

26

65

419

Cooper

1981

1 reference

10.1002/1097-0142(19901101)66:9<1869::AID-CNCR2820660903>3.0.CO;2-S

https://api.crossref.org/works/10.1002/1097-0142(19901101)66:9%3C1869::AID-CNCR2820660903%3E3.0.CO;2-S

2 November 2022

Identifiers

10.1002/1097-0142(19901101)66:9<1869::AID-CNCR2820660903>3.0.CO;2-S

1 reference

5 December 2017

1 reference